JNJ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
JNJ is a good buy right now for a beginner focused on long-term investing. The stock has a constructive technical setup, supportive analyst revisions, positive congress buying, and solid business fundamentals. The main reason to buy now is that the shares are already showing strength above key moving averages, and long-term upside appears supported by drug pipeline momentum and steady core growth. Given the investor profile and available capital, JNJ is suitable as a core long-term position today rather than waiting for a perfect entry.
JNJ is in a clear short-term uptrend. Price closed at 262.40, above the pivot at 245.83 and near resistance levels at R1 259.43 and R2 267.83. The moving averages are bullish with SMA_5 > SMA_20 > SMA_200, confirming trend strength. MACD histogram is positive at 2.512 and expanding, which supports continued momentum. RSI_6 is 80.57, which signals overbought conditions, so near-term upside may be choppy, but the broader trend remains bullish.
Analyst sentiment has improved recently: Leerink upgraded JNJ to Outperform with a $265 target, Guggenheim raised its target to $266 and kept Buy, Morgan Stanley raised its target to $283 and kept Overweight, RBC raised its target to $265 and kept Outperform, and TD Cowen initiated Buy coverage with a $250 target. News flow highlights strong company scale, with Q1 2026 revenue at $24.06B and continued confidence in healthcare leadership. Congress trading data is also supportive, with 1 purchase transaction in the recent 90 days and no sales reported. The upcoming Q2 2026 earnings on 2026-07-15 is a potential catalyst.
Insiders have been selling, and the selling amount increased 159.20% over the last month, which is the clearest negative signal in the data. Options activity is not strongly bullish, with put volume heavier than call volume. The RSI is overbought, so the stock may pause or pull back short term after its recent run. Hedge funds are neutral and there are no significant trading trends over the last quarter, which limits institutional conviction.
Latest quarter shown: Q1 2026. Johnson & Johnson reported revenue of $24.06B, which indicates continued large-scale operating strength. Analyst commentary points to a beat-and-raise quarter, strong Tremfya uptake, successful ICOTYDE adoption, steady MedTech end-markets, and six consecutive quarters of double-digit organic growth in pharma. The financial trend appears positive, with growth coming from both new product momentum and stable core businesses.
Analyst ratings have trended upward recently. Multiple firms raised price targets in April and May 2026, and several maintained Buy/Outperform or Overweight ratings. Leerink’s upgrade to Outperform and target increase to $265 is the most recent move, reinforcing positive sentiment. Wall Street’s pro case is strong pipeline momentum, accelerating revenue growth, and durable growth in pharma and MedTech. The con case is more cautious: some firms remain Neutral/Equal Weight, and a few describe the latest quarter as solid but not thesis-changing. Overall, the analyst community is leaning bullish.
